Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) FCF Margin (2016 - 2025)

Historic FCF Margin for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to 233.25%.

  • Voyager Therapeutics' FCF Margin fell 1186400.0% to 233.25% in Q3 2025 from the same period last year, while for Sep 2025 it was 378.79%, marking a year-over-year decrease of 3613000.0%. This contributed to the annual value of 23.54% for FY2024, which is 534000.0% down from last year.
  • Latest data reveals that Voyager Therapeutics reported FCF Margin of 233.25% as of Q3 2025, which was down 1186400.0% from 660.88% recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' FCF Margin registered a high of 5197.26% during Q1 2022, and its lowest value of 2743.96% during Q2 2022.
  • In the last 5 years, Voyager Therapeutics' FCF Margin had a median value of 114.6% in 2024 and averaged 120.0%.
  • Its FCF Margin has fluctuated over the past 5 years, first skyrocketed by 55305800bps in 2022, then tumbled by -51154900bps in 2023.
  • Quarter analysis of 5 years shows Voyager Therapeutics' FCF Margin stood at 38.64% in 2021, then surged by 2100bps to 850.13% in 2022, then crashed by -103bps to 27.22% in 2023, then crashed by -759bps to 233.9% in 2024, then grew by 0bps to 233.25% in 2025.
  • Its FCF Margin stands at 233.25% for Q3 2025, versus 660.88% for Q2 2025 and 593.12% for Q1 2025.